RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+4.94%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$977M
AUM Growth
+$977M
(+20%)
Cap. Flow
+$140M
Cap. Flow
% of AUM
14.32%
Top 10 Holdings %
Top 10 Hldgs %
25.96%
Holding
96
New
4
Increased
44
Reduced
31
Closed
7
Top Buys
| 1 |
Nektar Therapeutics
NKTR
|
$20M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
$15.3M |
| 3 |
Incyte
INCY
|
$15.1M |
| 4 |
AET
Aetna Inc
AET
|
$12.8M |
| 5 |
Sangamo Therapeutics
SGMO
|
$11.3M |
Top Sells
| 1 |
AbbVie
ABBV
|
$12.7M |
| 2 |
Biogen
BIIB
|
$8.5M |
| 3 |
CELG
Celgene Corp
CELG
|
$6.81M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
$6.58M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$6.21M |
Sector Composition
| 1 | Healthcare | 91.68% |
| 2 | Financials | 1.43% |
| 3 | Energy | 0.15% |
| 4 | Technology | 0.13% |
| 5 | Communication Services | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Nektar Therapeutics
NKTR
$568M
| $30.2M | 3.09% | 617,652 +410,194 | +198% | +$20M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $27M | 2.77% | 1,632,212 -375,000 | -19% | -$6.21M |
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $26.3M | 2.7% | 155,000 +5,000 | +3% | +$850K |
|
|
4
Incyte
INCY
$16.5B
| $25.7M | 2.63% | 383,763 +224,800 | +141% | +$15.1M |
|
|
ABMD
5
DELISTED
Abiomed Inc
ABMD
| $24.7M | 2.53% | 60,400 -16,090 | -21% | -$6.58M |
|
6
Bristol-Myers Squibb
BMY
$96B
| $24.4M | 2.49% | 440,000 +90,000 | +26% | +$4.98M |
|
7
CVS Health
CVS
$92.8B
| $24.1M | 2.46% | 373,868 +120,000 | +47% | +$7.72M |
|
8
Medtronic
MDT
$119B
| $24M | 2.45% | 279,874 +68,591 | +32% | +$5.87M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $23.8M | 2.44% | 191,863 -30,000 | -14% | -$3.72M |
|
10
UnitedHealth
UNH
$281B
| $23.6M | 2.41% | 96,000 +15,000 | +19% | +$3.68M |
|
|
ESRX
11
DELISTED
Express Scripts Holding Company
ESRX
| $22.8M | 2.33% | 295,000 +80,000 | +37% | +$6.18M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $22.6M | 2.31% | 239,849 +35,000 | +17% | +$3.3M |
|
13
Cigna
CI
$80.3B
| $22.2M | 2.27% | 130,400 +20,000 | +18% | +$3.4M |
|
14
Jazz Pharmaceuticals
JAZZ
$7.75B
| $22.1M | 2.26% | 128,436 -20,000 | -13% | -$3.45M |
|
15
Humana
HUM
$36.5B
| $21.7M | 2.22% | 73,000 +5,000 | +7% | +$1.49M |
|
|
LOXO
16
DELISTED
Loxo Oncology, Inc
LOXO
| $21.3M | 2.18% | 122,961 +47,961 | +64% | +$8.32M |
|
|
AGN
17
DELISTED
Allergan plc
AGN
| $20.8M | 2.13% | 125,045 +65,045 | +108% | +$10.8M |
|
18
Becton Dickinson
BDX
$55.3B
| $20.4M | 2.08% | 85,000 +10,000 | +13% | +$2.4M |
|
|
SAGE
19
DELISTED
Sage Therapeutics
SAGE
| $20.3M | 2.08% | 129,679 +34,679 | +37% | +$5.43M |
|
20
Exelixis
EXEL
$10.1B
| $20.3M | 2.07% | 941,214 -45,000 | -5% | -$968K |
|
|
WBA
21
DELISTED
Walgreens Boots Alliance
WBA
| $19.8M | 2.03% | 330,000 +255,000 | +340% | +$15.3M |
|
22
Gilead Sciences
GILD
$140B
| $18.6M | 1.9% | 262,027 +25,000 | +11% | +$1.77M |
|
23
Elevance Health
ELV
$71.8B
| $18.1M | 1.85% | 76,000 +15,000 | +25% | +$3.57M |
|
24
Eli Lilly
LLY
$657B
| $17.1M | 1.75% | 200,000 -22,859 | -10% | -$1.95M |
|
|
CELG
25
DELISTED
Celgene Corp
CELG
| $16.7M | 1.71% | 210,698 -85,714 | -29% | -$6.81M |
|